메뉴 건너뛰기




Volumn 108, Issue 1, 2016, Pages

Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

EID: 84951906637     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv292     Document Type: Review
Times cited : (51)

References (133)
  • 1
    • 84892370875 scopus 로고    scopus 로고
    • Increasing value and reducing waste in research design, conduct, and analysis
    • Ioannidis JPA, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383(9912):166-175.
    • (2014) Lancet , vol.383 , Issue.9912 , pp. 166-175
    • Ioannidis, J.P.A.1    Greenland, S.2    Hlatky, M.A.3
  • 2
    • 84892142354 scopus 로고    scopus 로고
    • How to increase value and reduce waste when research priorities are set
    • Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383(9912):156-165.
    • (2014) Lancet , vol.383 , Issue.9912 , pp. 156-165
    • Chalmers, I.1    Bracken, M.B.2    Djulbegovic, B.3
  • 4
    • 84892390898 scopus 로고    scopus 로고
    • Development times clinical testing postmarket follow-up and safety risks for the new drugs approved by the US Food and Drug Administration: The class of 2008
    • Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration: the class of 2008. JAMA Int Med. 2014;174(1):90-95.
    • (2014) JAMA Int Med , vol.174 , Issue.1 , pp. 90-95
    • Moore, T.J.1    Furberg, C.D.2
  • 5
    • 4344645978 scopus 로고    scopus 로고
    • Can the pharmaceutical industry reduce attrition rates
    • Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates Nat Rev Drug Discov. 2004;3(8):711-716.
    • (2004) Nat Rev Drug Discov , vol.3 , Issue.8 , pp. 711-716
    • Kola, I.1    Landis, J.2
  • 7
    • 84875367623 scopus 로고    scopus 로고
    • President's Council of Advisors on Science and Technology (U.S.) Executive Office of the President, President's Council of Advisors on Science and Technology. Washington, D.C.;
    • President's Council of Advisors on Science and Technology (U.S.). Report to the President On Propelling Innovation in Drug Discovery, Development, and Evaluation. Executive Office of the President, President's Council of Advisors on Science and Technology. Washington, D.C.; 2012.
    • (2012) Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation
  • 8
    • 84255183718 scopus 로고    scopus 로고
    • Accelerating identification and regulatory approval of investigational cancer drugs
    • Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011;306(23):2608-2609.
    • (2011) JAMA , vol.306 , Issue.23 , pp. 2608-2609
    • Esserman, L.J.1    Woodcock, J.2
  • 9
    • 33746551430 scopus 로고    scopus 로고
    • U.S. Department of Health and Human Services Food and Drug Administration
    • U.S. Department of Health and Human Services, Food and Drug Administration. Critical Path Opportunities Report, 2006.
    • (2006) Critical Path Opportunities Report
  • 10
    • 79960100831 scopus 로고    scopus 로고
    • Reengineering translational science: The time is right
    • Collins FS. Reengineering translational science: the time is right. Sci Trans Med. 2011;3(90):90cm17-90cm17.
    • (2011) Sci Trans Med , vol.3 , Issue.90 , pp. 90cm17-90cm17
    • Collins, F.S.1
  • 11
    • 10744228140 scopus 로고    scopus 로고
    • CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
    • Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181.
    • (2003) Semin Radiat Oncol , vol.13 , Issue.3 , pp. 176-181
    • Trotti, A.1    Colevas, A.D.2    Setser, A.3
  • 12
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205-216.
    • (2000) J Natl Cancer Inst , vol.92 , Issue.3 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 13
  • 14
    • 19944431093 scopus 로고    scopus 로고
    • A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
    • Fiedler W, Serve H, Döhner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105(3):986-993.
    • (2005) Blood , vol.105 , Issue.3 , pp. 986-993
    • Fiedler, W.1    Serve, H.2    Döhner, H.3
  • 15
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24.
    • (2006) J Clin Oncol , vol.24 , Issue.1 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3
  • 16
    • 33644847440 scopus 로고    scopus 로고
    • Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    • Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35.
    • (2006) J Clin Oncol , vol.24 , Issue.1 , pp. 25-35
    • Faivre, S.1    Delbaldo, C.2    Vera, K.3
  • 17
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-2524.
    • (2006) JAMA , vol.295 , Issue.21 , pp. 2516-2524
    • Motzer, R.J.1    Rini, B.I.2    Bukowski, R.M.3
  • 18
    • 33646108821 scopus 로고    scopus 로고
    • Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase i study in healthy subjects
    • Bello Carlo L, Sherman Laurie, Zhou Jihao, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs. 2006;17(3):353-358.
    • (2006) Anticancer Drugs , vol.17 , Issue.3 , pp. 353-358
    • Bello Carlo, L.1    Laurie, S.2    Jihao, Z.3
  • 19
    • 33749505836 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomised controlled trial
    • Demetri GD, Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-1338.
    • (2006) Lancet , vol.368 , Issue.9544 , pp. 1329-1338
    • Demetri, G.D.1    Oosterom, A.T.2    Garrett, C.R.3
  • 20
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.
    • (2007) N Engl J Med , vol.356 , Issue.2 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 21
    • 37249072373 scopus 로고    scopus 로고
    • A phase i and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
    • Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61(3):515-524.
    • (2008) Cancer Chemother Pharmacol , vol.61 , Issue.3 , pp. 515-524
    • Britten, C.D.1    Kabbinavar, F.2    Hecht, J.R.3
  • 22
    • 36048992408 scopus 로고    scopus 로고
    • Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
    • Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25(30):4793-4799.
    • (2007) J Clin Oncol , vol.25 , Issue.30 , pp. 4793-4799
    • Saltz, L.B.1    Rosen, L.S.2    Marshall, J.L.3
  • 23
    • 39149120621 scopus 로고    scopus 로고
    • Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    • Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(4):650-656.
    • (2008) J Clin Oncol , vol.26 , Issue.4 , pp. 650-656
    • Socinski, M.A.1    Novello, S.2    Brahmer, J.R.3
  • 24
    • 42949148257 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    • Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26(11):1810-1816.
    • (2008) J Clin Oncol , vol.26 , Issue.11 , pp. 1810-1816
    • Burstein, H.J.1    Elias, A.D.2    Rugo, H.S.3
  • 25
    • 49149114782 scopus 로고    scopus 로고
    • Activity of sunitinib in patients with advanced neuroendocrine tumors
    • Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403-3410.
    • (2008) J Clin Oncol , vol.26 , Issue.20 , pp. 3403-3410
    • Kulke, M.H.1    Lenz, H.J.2    Meropol, N.J.3
  • 26
    • 49249087039 scopus 로고    scopus 로고
    • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    • Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26(22):3743-3748.
    • (2008) J Clin Oncol , vol.26 , Issue.22 , pp. 3743-3748
    • Rini, B.I.1    Michaelson, M.D.2    Rosenberg, J.E.3
  • 27
    • 58149181329 scopus 로고    scopus 로고
    • Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma
    • Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181(2):518-523.
    • (2009) J Urol , vol.181 , Issue.2 , pp. 518-523
    • Thomas, A.A.1    Rini, B.I.2    Lane, B.R.3
  • 28
    • 62849099971 scopus 로고    scopus 로고
    • Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib
    • Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2008;76(5):350-354.
    • (2008) Oncology , vol.76 , Issue.5 , pp. 350-354
    • Zimmermann, K.1    Schmittel, A.2    Steiner, U.3
  • 29
    • 67650472798 scopus 로고    scopus 로고
    • Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
    • Janeway KA, Albritton KH, Van Den Abbeele AD, et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Ped Blood Cancer. 2009;52(7):767-771.
    • (2009) Ped Blood Cancer , vol.52 , Issue.7 , pp. 767-771
    • Janeway, K.A.1    Albritton, K.H.2    Van Den Abbeele, A.D.3
  • 30
    • 65549099731 scopus 로고    scopus 로고
    • Phase II study of sunitinib in men with advanced prostate cancer
    • Michaelson MD, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol. 2009;20(5):913-920.
    • (2009) Ann Oncol , vol.20 , Issue.5 , pp. 913-920
    • Michaelson, M.D.1    Regan, M.M.2    Oh, W.K.3
  • 31
    • 67650312341 scopus 로고    scopus 로고
    • Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
    • George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27(19):3154-3160.
    • (2009) J Clin Oncol , vol.27 , Issue.19 , pp. 3154-3160
    • George, S.1    Merriam, P.2    Maki, R.G.3
  • 32
    • 67649946279 scopus 로고    scopus 로고
    • Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
    • Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27(18):3027-3035.
    • (2009) J Clin Oncol , vol.27 , Issue.18 , pp. 3027-3035
    • Zhu, A.X.1    Sahani, D.V.2    Duda, D.G.3
  • 33
    • 77956621875 scopus 로고    scopus 로고
    • Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors
    • Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010;28(4):523-528.
    • (2010) Invest New Drugs , vol.28 , Issue.4 , pp. 523-528
    • Feldman, D.R.1    Turkula, S.2    Ginsberg, M.S.3
  • 34
    • 67651165187 scopus 로고    scopus 로고
    • Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicenter, phase II study
    • Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicenter, phase II study. Lancet Oncol. 2009;10(8):794-800.
    • (2009) Lancet Oncol , vol.10 , Issue.8 , pp. 794-800
    • Faivre, S.1    Raymond, E.2    Boucher, E.3
  • 35
    • 70450211684 scopus 로고    scopus 로고
    • Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
    • Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2009:mdp323.
    • (2009) Ann Oncol , pp. mdp323
    • Sonpavde, G.1    Periman, P.O.2    Bernold, D.3
  • 36
    • 70249084594 scopus 로고    scopus 로고
    • Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
    • Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4068-4075.
    • (2009) J Clin Oncol , vol.27 , Issue.25 , pp. 4068-4075
    • Escudier, B.1    Roigas, J.2    Gillessen, S.3
  • 37
    • 77956056104 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate in head and neck squamous cell carcinoma
    • Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010;28(5):677-683.
    • (2010) Invest New Drugs , vol.28 , Issue.5 , pp. 677-683
    • Choong, N.W.1    Kozloff, M.2    Taber, D.3
  • 38
    • 75749105462 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
    • Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol. 2010;65(4):649-660.
    • (2010) Cancer Chemother Pharmacol , vol.65 , Issue.4 , pp. 649-660
    • Fountzilas, G.1    Fragkoulidi, A.2    Kalogera-Fountzila, A.3
  • 39
    • 78549246206 scopus 로고    scopus 로고
    • Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    • Shirao K, Nishida T, Doi T, et al. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2010;28(6):866-875.
    • (2010) Invest New Drugs , vol.28 , Issue.6 , pp. 866-875
    • Shirao, K.1    Nishida, T.2    Doi, T.3
  • 40
    • 74249122456 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184
    • Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184. Gynecol Oncol. 2010;116(2):163-167.
    • (2010) Gynecol Oncol , vol.116 , Issue.2 , pp. 163-167
    • Mackay, H.J.1    Tinker, A.2    Winquist, E.3
  • 41
    • 77954843443 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function
    • Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol. 2010;50(4):472-481.
    • (2010) J Clin Pharmacol , vol.50 , Issue.4 , pp. 472-481
    • Khosravan, R.1    Toh, M.2    Garrett, M.3
  • 42
    • 70350569370 scopus 로고    scopus 로고
    • Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
    • Hensley ML, Sill MW, Scribner DR, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2009;115(3):460-465.
    • (2009) Gynecol Oncol , vol.115 , Issue.3 , pp. 460-465
    • Hensley, M.L.1    Sill, M.W.2    Scribner, D.R.3
  • 43
    • 70350655546 scopus 로고    scopus 로고
    • Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    • Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer. 2009;101(9):1543-1548.
    • (2009) Br J Cancer , vol.101 , Issue.9 , pp. 1543-1548
    • Novello, S.1    Scagliotti, G.V.2    Rosell, R.3
  • 44
    • 77950348305 scopus 로고    scopus 로고
    • A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: Insights into the treatment, efficacy and safety
    • Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol. 2010;40(3):194-202.
    • (2010) Jpn J Clin Oncol , vol.40 , Issue.3 , pp. 194-202
    • Uemura, H.1    Shinohara, N.2    Yuasa, T.3
  • 45
    • 73949143686 scopus 로고    scopus 로고
    • Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01
    • Machiels JPH, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010;28(1):21-28.
    • (2010) J Clin Oncol , vol.28 , Issue.1 , pp. 21-28
    • MacHiels, J.P.H.1    Henry, S.2    Zanetta, S.3
  • 46
    • 77950474660 scopus 로고    scopus 로고
    • Phase II study of sunitinib in patients with metastatic urothelial cancer
    • Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28(8):1373-1379.
    • (2010) J Clin Oncol , vol.28 , Issue.8 , pp. 1373-1379
    • Gallagher, D.J.1    Milowsky, M.I.2    Gerst, S.R.3
  • 47
    • 77950546450 scopus 로고    scopus 로고
    • Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06)
    • Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-292.
    • (2010) Oncologist , vol.15 , Issue.3 , pp. 285-292
    • Koeberle, D.1    Montemurro, M.2    Samaras, P.3
  • 48
    • 82955241985 scopus 로고    scopus 로고
    • Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    • Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011;29(6):1449-1458.
    • (2011) Invest New Drugs , vol.29 , Issue.6 , pp. 1449-1458
    • Bang, Y.J.1    Kang, Y.K.2    Kang, W.K.3
  • 49
    • 77956187531 scopus 로고    scopus 로고
    • Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
    • Wildiers H, Fontaine C, Vuylsteke P, et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010;123(2):463-469.
    • (2010) Breast Cancer Res Treat , vol.123 , Issue.2 , pp. 463-469
    • Wildiers, H.1    Fontaine, C.2    Vuylsteke, P.3
  • 50
    • 77957068128 scopus 로고    scopus 로고
    • Phase II study of sunitinib in patients with primary or Post-Polycythemia vera/essential thrombocythemia myelofibrosis
    • Apostolidou E, Kantarjian H, Thomas D, Burger I, Borthakur G, Verstovsek S. Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Clin Lymphoma Myeloma Leukemia. 2010;10(4):281-284.
    • (2010) Clin Lymphoma Myeloma Leukemia , vol.10 , Issue.4 , pp. 281-284
    • Apostolidou, E.1    Kantarjian, H.2    Thomas, D.3    Burger, I.4    Borthakur, G.5    Verstovsek, S.6
  • 51
    • 79251585977 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study
    • Biagi JJ, Oza AM, Chalchal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol. 2011;22(2):335-340.
    • (2011) Ann Oncol , vol.22 , Issue.2 , pp. 335-340
    • Biagi, J.J.1    Oza, A.M.2    Chalchal, H.I.3
  • 52
    • 77956642234 scopus 로고    scopus 로고
    • Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma
    • Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184(3):859-864.
    • (2010) J Urol , vol.184 , Issue.3 , pp. 859-864
    • Hellenthal, N.J.1    Underwood, W.2    Penetrante, R.3
  • 53
    • 78049462514 scopus 로고    scopus 로고
    • Phase II study of daily sunitinib in fdgpet-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation
    • Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in fdgpet-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260-5268.
    • (2010) Clin Cancer Res , vol.16 , Issue.21 , pp. 5260-5268
    • Carr, L.L.1    Mankoff, D.A.2    Goulart, B.H.3
  • 54
    • 79959795987 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate in patients with recurrent high-grade glioma
    • Neyns B, Sadones J, Chaskis C, et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol. 2011;103(3):491-501.
    • (2011) J Neurooncol , vol.103 , Issue.3 , pp. 491-501
    • Neyns, B.1    Sadones, J.2    Chaskis, C.3
  • 55
    • 78650988960 scopus 로고    scopus 로고
    • A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)
    • O'Reilly EM, Niedzwiecki D, Hall M, et al. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010;15(12):1310-1319.
    • (2010) Oncologist , vol.15 , Issue.12 , pp. 1310-1319
    • O'Reilly, E.M.1    Niedzwiecki, D.2    Hall, M.3
  • 56
    • 79851482955 scopus 로고    scopus 로고
    • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    • Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513.
    • (2011) N Engl J Med , vol.364 , Issue.6 , pp. 501-513
    • Raymond, E.1    Dahan, L.2    Raoul, J.L.3
  • 57
    • 79960860865 scopus 로고    scopus 로고
    • Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: A Canadian Urol Oncol Group/German Testicular Cancer Study Group cooperative study
    • Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urol Oncol Group/German Testicular Cancer Study Group cooperative study. Ann Oncol. 2011;22(12):2654-2660.
    • (2011) Ann Oncol , vol.22 , Issue.12 , pp. 2654-2660
    • Oechsle, K.1    Honecker, F.2    Cheng, T.3
  • 58
    • 80053270703 scopus 로고    scopus 로고
    • Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
    • Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646-2653.
    • (2011) Ann Oncol , vol.22 , Issue.12 , pp. 2646-2653
    • Bellmunt, J.1    Gonzalez-Larriba, J.L.2    Prior, C.3
  • 59
    • 80051631789 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma
    • Mahmood ST, Agresta S, Vigil CE, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011;129(8):1963-1969.
    • (2011) Int J Cancer , vol.129 , Issue.8 , pp. 1963-1969
    • Mahmood, S.T.1    Agresta, S.2    Vigil, C.E.3
  • 60
    • 79955066221 scopus 로고    scopus 로고
    • Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: A clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
    • Buckstein R, Kuruvilla J, Chua N, et al. Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leukemia Lymphoma. 2011;52(5):833-841.
    • (2011) Leukemia Lymphoma , vol.52 , Issue.5 , pp. 833-841
    • Buckstein, R.1    Kuruvilla, J.2    Chua, N.3
  • 61
    • 79958803154 scopus 로고    scopus 로고
    • An open-label multicenter biomarker-oriented AIO phase II trial of sunitinib for patients with chemorefractory advanced gastric cancer
    • Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicenter biomarker-oriented AIO phase II trial of sunitinib for patients with chemorefractory advanced gastric cancer Eur J Cancer. 2011;47(10):1511-1520.
    • (2011) Eur J Cancer , vol.47 , Issue.10 , pp. 1511-1520
    • Moehler, M.1    Mueller, A.2    Hartmann, J.T.3
  • 62
    • 79958111411 scopus 로고    scopus 로고
    • Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer
    • Schneider BJ, Gadgeel SM, Ramnath N, et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6(6):1117-1120.
    • (2011) J Thorac Oncol , vol.6 , Issue.6 , pp. 1117-1120
    • Schneider, B.J.1    Gadgeel, S.M.2    Ramnath, N.3
  • 63
    • 79959549917 scopus 로고    scopus 로고
    • Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): A randomised phase 2 trial
    • Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12(7):673-680.
    • (2011) Lancet Oncol , vol.12 , Issue.7 , pp. 673-680
    • Négrier, S.1    Gravis, G.2    Pérol, D.3
  • 64
    • 82955240710 scopus 로고    scopus 로고
    • Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: A single-center study in Turkey
    • Yildiz I, Sen F, Basaran M, et al. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey. Jpn J Clin Oncol. 2011:41(12):1380-1387.
    • (2011) Jpn J Clin Oncol , vol.41 , Issue.12 , pp. 1380-1387
    • Yildiz, I.1    Sen, F.2    Basaran, M.3
  • 65
    • 82355175370 scopus 로고    scopus 로고
    • Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease
    • Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011;22(12):2661-2666.
    • (2011) Ann Oncol , vol.22 , Issue.12 , pp. 2661-2666
    • Jonasch, E.1    McCutcheon, I.E.2    Waguespack, S.G.3
  • 66
    • 79960983264 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A children's oncology group study
    • DuBois SG, Shusterman S, Ingle AM, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011;17(15):5113-5122.
    • (2011) Clin Cancer Res , vol.17 , Issue.15 , pp. 5113-5122
    • DuBois, S.G.1    Shusterman, S.2    Ingle, A.M.3
  • 67
    • 80053907517 scopus 로고    scopus 로고
    • A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ
    • Bex A, Blank C, Meinhardt W, Tinteren H, Horenblas S, Haanen J. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology. 2011;78(4):832-837.
    • (2011) Urology , vol.78 , Issue.4 , pp. 832-837
    • Bex, A.1    Blank, C.2    Meinhardt, W.3    Tinteren, H.4    Horenblas, S.5    Haanen, J.6
  • 68
    • 84898700985 scopus 로고    scopus 로고
    • Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mrcc): Preliminary results
    • Barrios CH, Hernandez-Barajas D, Brown MP, et al. Phase ii trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mrcc): preliminary results. Eur J Cancer Suppl. 2009;7(2):429-430.
    • (2009) Eur J Cancer Suppl , vol.7 , Issue.2 , pp. 429-430
    • Barrios, C.H.1    Hernandez-Barajas, D.2    Brown, M.P.3
  • 69
    • 80054897151 scopus 로고    scopus 로고
    • Brief report: A phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group
    • Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol. 2011;6(11):1950-1954.
    • (2011) J Thorac Oncol , vol.6 , Issue.11 , pp. 1950-1954
    • Laurie, S.A.1    Gupta, A.2    Chu, Q.3
  • 70
    • 84861747033 scopus 로고    scopus 로고
    • A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: Current progress and challenges in evaluating molecularly targeted agents in ACC
    • Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23(6):1562-1570.
    • (2012) Ann Oncol , vol.23 , Issue.6 , pp. 1562-1570
    • Chau, N.G.1    Hotte, S.J.2    Chen, E.X.3
  • 71
    • 84655161964 scopus 로고    scopus 로고
    • A phase II study of sunitinib as a secondline treatment in advanced biliary tract carcinoma: A multicenter, multinational study
    • Yi JH, Thongprasert S, Lee J, et al. A phase II study of sunitinib as a secondline treatment in advanced biliary tract carcinoma: a multicenter, multinational study. Eur J Cancer. 2012;48(2):196-201.
    • (2012) Eur J Cancer , vol.48 , Issue.2 , pp. 196-201
    • Yi, J.H.1    Thongprasert, S.2    Lee, J.3
  • 72
    • 84856550225 scopus 로고    scopus 로고
    • Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
    • Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2012;30(1):335-340.
    • (2012) Invest New Drugs , vol.30 , Issue.1 , pp. 335-340
    • Molina, A.M.1    Feldman, D.R.2    Ginsberg, M.S.3
  • 73
    • 84865573372 scopus 로고    scopus 로고
    • A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
    • Strosberg JR, Weber JM, Choi J, et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012;23(9):2335-2341.
    • (2012) Ann Oncol , vol.23 , Issue.9 , pp. 2335-2341
    • Strosberg, J.R.1    Weber, J.M.2    Choi, J.3
  • 74
    • 84872869916 scopus 로고    scopus 로고
    • A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
    • Campos SM, Penson RT, Matulonis U, et al. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013;128(2):215-220.
    • (2013) Gynecol Oncol , vol.128 , Issue.2 , pp. 215-220
    • Campos, S.M.1    Penson, R.T.2    Matulonis, U.3
  • 75
    • 84872157738 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer
    • Han JY, Kim HY, Lim KY, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013;79(2):137-142.
    • (2013) Lung Cancer , vol.79 , Issue.2 , pp. 137-142
    • Han, J.Y.1    Kim, H.Y.2    Lim, K.Y.3
  • 76
    • 84859801305 scopus 로고    scopus 로고
    • Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: A Childrenâ™s Oncology Group study
    • DuBois SG, Shusterman S, Reid JM, et al. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Childrenâ™s Oncology Group study. Cancer Chemother Pharmacol. 2012;69(4):1021-1027.
    • (2012) Cancer Chemother Pharmacol , vol.69 , Issue.4 , pp. 1021-1027
    • DuBois, S.G.1    Shusterman, S.2    Reid, J.M.3
  • 77
    • 84865556743 scopus 로고    scopus 로고
    • A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
    • Baumann KH, Du Bois A, Meier W, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol. 2012;23(9):2265-2271.
    • (2012) Ann Oncol , vol.23 , Issue.9 , pp. 2265-2271
    • Baumann, K.H.1    Du Bois, A.2    Meier, W.3
  • 78
    • 84866746182 scopus 로고    scopus 로고
    • The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study
    • Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol. 2012;30(5):704-710.
    • (2012) Urol Oncol , vol.30 , Issue.5 , pp. 704-710
    • Baldazzi, V.1    Tassi, R.2    Lapini, A.3    Santomaggio, C.4    Carini, M.5    Mazzanti, R.6
  • 79
    • 84860286851 scopus 로고    scopus 로고
    • Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell
    • Staehler M, Haseke N, Stadler T, et al. Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. 2012;30(3):290-293.
    • (2012) Cancer , vol.30 , Issue.3 , pp. 290-293
    • Staehler, M.1    Haseke, N.2    Stadler, T.3
  • 80
    • 84864922628 scopus 로고    scopus 로고
    • Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
    • Lee JL, Ahn JH, Lim HY, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol. 2012;23(8):2108-2114.
    • (2012) Ann Oncol , vol.23 , Issue.8 , pp. 2108-2114
    • Lee, J.L.1    Ahn, J.H.2    Lim, H.Y.3
  • 81
    • 84860355062 scopus 로고    scopus 로고
    • Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma
    • Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30(12):1371-1377.
    • (2012) J Clin Oncol , vol.30 , Issue.12 , pp. 1371-1377
    • Motzer, R.J.1    Hutson, T.E.2    Olsen, M.R.3
  • 82
    • 84863411111 scopus 로고    scopus 로고
    • The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery
    • Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol. 2012;187(5):1548-1554.
    • (2012) J Urol , vol.187 , Issue.5 , pp. 1548-1554
    • Rini, B.I.1    Garcia, J.2    Elson, P.3
  • 83
    • 84858284399 scopus 로고    scopus 로고
    • Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma
    • Flörcken A, Takvorian A, Van Lessen A, et al. Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma. Anticancer Drugs. 2012;23(3):298-302.
    • (2012) Anticancer Drugs , vol.23 , Issue.3 , pp. 298-302
    • Flörcken, A.1    Takvorian, A.2    Van Lessen, A.3
  • 84
    • 84886298776 scopus 로고    scopus 로고
    • Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence
    • Zhao J, Zhu Y, Zhang C, et al. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Urol Oncol. 2013;31(8):1800-1805.
    • (2013) Urol Oncol , vol.31 , Issue.8 , pp. 1800-1805
    • Zhao, J.1    Zhu, Y.2    Zhang, C.3
  • 85
    • 84862997356 scopus 로고    scopus 로고
    • Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases
    • Tong CCL, Ko EC, Sung MW, et al. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PloS One. 2012;7(6):e36979.
    • (2012) PloS One , vol.7 , Issue.6 , pp. e36979
    • Tong, C.C.L.1    Ko, E.C.2    Sung, M.W.3
  • 86
    • 84868532639 scopus 로고    scopus 로고
    • A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma
    • Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012;62(6):1013-1019.
    • (2012) Eur Urol , vol.62 , Issue.6 , pp. 1013-1019
    • Tannir, N.M.1    Plimack, E.2    Ng, C.3
  • 87
    • 84861786753 scopus 로고    scopus 로고
    • Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
    • Demetri GD, Garrett CR, Schöffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res. 2012;18(11):3170-3179.
    • (2012) Clin Cancer Res , vol.18 , Issue.11 , pp. 3170-3179
    • Demetri, G.D.1    Garrett, C.R.2    Schöffski, P.3
  • 88
    • 84866364645 scopus 로고    scopus 로고
    • A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
    • Pan E, Yu D, Yue B, et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol. 2012;110(1):111-118.
    • (2012) J Neurooncol , vol.110 , Issue.1 , pp. 111-118
    • Pan, E.1    Yu, D.2    Yue, B.3
  • 89
    • 84867255648 scopus 로고    scopus 로고
    • Sunitinib in refractory adrenocortical carcinoma: A phase II, single-arm, open-label trial
    • Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metabol. 2012;97(10):3495-3503.
    • (2012) J Clin Endocrinol Metabol , vol.97 , Issue.10 , pp. 3495-3503
    • Kroiss, M.1    Quinkler, M.2    Johanssen, S.3
  • 90
    • 84865687005 scopus 로고    scopus 로고
    • A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma
    • Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012;7(9):1449-1456.
    • (2012) J Thorac Oncol , vol.7 , Issue.9 , pp. 1449-1456
    • Nowak, A.K.1    Millward, M.J.2    Creaney, J.3
  • 91
    • 84878757035 scopus 로고    scopus 로고
    • Phase II open-label study of sunitinib in patients with advanced breast cancer
    • Yardley DA, Dees EC, Myers SD, et al. Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Res Treat. 2012;136(3):759-767.
    • (2012) Breast Cancer Res Treat , vol.136 , Issue.3 , pp. 759-767
    • Yardley, D.A.1    Dees, E.C.2    Myers, S.D.3
  • 92
    • 84871816644 scopus 로고    scopus 로고
    • Continuous daily sunitinib for recurrent glioblastoma
    • Kreisl TN, Smith P, Sul J, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2013;111(1):41-48.
    • (2013) J Neurooncol , vol.111 , Issue.1 , pp. 41-48
    • Kreisl, T.N.1    Smith, P.2    Sul, J.3
  • 93
    • 84877339187 scopus 로고    scopus 로고
    • Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients
    • Neri B, Vannini A, Brugia M, et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients. Int J Urol. 2013;20(5):478-483.
    • (2013) Int J Urol , vol.20 , Issue.5 , pp. 478-483
    • Neri, B.1    Vannini, A.2    Brugia, M.3
  • 94
  • 95
    • 84884817266 scopus 로고    scopus 로고
    • Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
    • Ito T, Okusaka T, Nishida T, et al. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs. 2013;31(5):1265-1274.
    • (2013) Invest New Drugs , vol.31 , Issue.5 , pp. 1265-1274
    • Ito, T.1    Okusaka, T.2    Nishida, T.3
  • 96
    • 84881552690 scopus 로고    scopus 로고
    • A phase II study of sunitinib in advanced hepatocellular carcinoma
    • Barone C, Basso M, Biolato M, et al. A phase II study of sunitinib in advanced hepatocellular carcinoma. Dig Liver Dis. 2013;45(8):692-698.
    • (2013) Dig Liver Dis , vol.45 , Issue.8 , pp. 692-698
    • Barone, C.1    Basso, M.2    Biolato, M.3
  • 97
    • 84884819341 scopus 로고    scopus 로고
    • Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial
    • Reynolds C, Spira AI, Gluck L, et al. Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial. Invest New Drugs. 2013;31(5):1330-1338.
    • (2013) Invest New Drugs , vol.31 , Issue.5 , pp. 1330-1338
    • Reynolds, C.1    Spira, A.I.2    Gluck, L.3
  • 98
    • 84886793895 scopus 로고    scopus 로고
    • Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
    • Reni M, Cereda S, Milella M, et al. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer. 2013;49(17):3609-3615.
    • (2013) Eur J Cancer , vol.49 , Issue.17 , pp. 3609-3615
    • Reni, M.1    Cereda, S.2    Milella, M.3
  • 99
    • 84884151634 scopus 로고    scopus 로고
    • Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
    • Curigliano G, Pivot X, Cortés J, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013;22(5):650-656.
    • (2013) Breast , vol.22 , Issue.5 , pp. 650-656
    • Curigliano, G.1    Pivot, X.2    Cortés, J.3
  • 100
    • 84882781441 scopus 로고    scopus 로고
    • Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.
    • (2013) N Engl J Med , vol.369 , Issue.8 , pp. 722-731
    • Motzer, R.J.1    Hutson, T.E.2    Cella, D.3
  • 101
    • 84891915708 scopus 로고    scopus 로고
    • Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
    • Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013:JCO-2012.
    • (2013) J Clin Oncol , pp. JCO-2012
    • Cheng, A.L.1    Kang, Y.K.2    Lin, D.Y.3
  • 102
    • 84885386248 scopus 로고    scopus 로고
    • Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    • Kim HR, Park HS, Kwon WS, et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013;72(4):825-835.
    • (2013) Cancer Chemother Pharmacol , vol.72 , Issue.4 , pp. 825-835
    • Kim, H.R.1    Park, H.S.2    Kwon, W.S.3
  • 103
    • 84892434422 scopus 로고    scopus 로고
    • A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases
    • Chevreau C, Ravaud A, Escudier B, et al. A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases. Clin Genitourin Cancer. 2014;12(1):50-54.
    • (2014) Clin Genitourin Cancer , vol.12 , Issue.1 , pp. 50-54
    • Chevreau, C.1    Ravaud, A.2    Escudier, B.3
  • 104
    • 84896703767 scopus 로고    scopus 로고
    • Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
    • Grivas PD, Daignault S, Tagawa ST, et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014;120(5):692-701.
    • (2014) Cancer , vol.120 , Issue.5 , pp. 692-701
    • Grivas, P.D.1    Daignault, S.2    Tagawa, S.T.3
  • 105
    • 84891527003 scopus 로고    scopus 로고
    • A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)
    • Hutterer M, Nowosielski M, Haybaeck J, et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro-oncol. 2014;16(1):92-102.
    • (2014) Neuro-oncol , vol.16 , Issue.1 , pp. 92-102
    • Hutterer, M.1    Nowosielski, M.2    Haybaeck, J.3
  • 106
    • 84919493168 scopus 로고    scopus 로고
    • Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: Results of a Phase II study
    • Balanã C, Gil MJ, Perez P, et al. Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study. Target Oncol. 2014;9(4):321-329.
    • (2014) Target Oncol , vol.9 , Issue.4 , pp. 321-329
    • Balanã, C.1    Gil, M.J.2    Perez, P.3
  • 107
    • 84902986833 scopus 로고    scopus 로고
    • Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study
    • Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014:JCO-2013.
    • (2014) J Clin Oncol , pp. JCO-2013
    • Escudier, B.1    Porta, C.2    Bono, P.3
  • 108
    • 84900526150 scopus 로고    scopus 로고
    • Pharmacokinetically guided sunitinib dosing: A feasibility study in patients with advanced solid tumors
    • Lankheet NAG, Kloth JSL, Hooijdonk CGM, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumors. Br J Cancer. 2014;110(10):2441-2449.
    • (2014) Br J Cancer , vol.110 , Issue.10 , pp. 2441-2449
    • Lankheet, N.A.G.1    Kloth, J.S.L.2    Hooijdonk, C.G.M.3
  • 109
    • 84905568519 scopus 로고    scopus 로고
    • A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret Chicago and California Consortia
    • Castonguay V, Lheureux S, Welch S, et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol. 2014;134(2):274-280.
    • (2014) Gynecol Oncol , vol.134 , Issue.2 , pp. 274-280
    • Castonguay, V.1    Lheureux, S.2    Welch, S.3
  • 110
    • 84906815674 scopus 로고    scopus 로고
    • Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma
    • Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014:JCO-2013.
    • (2014) J Clin Oncol , pp. JCO-2013
    • Motzer, R.J.1    Barrios, C.H.2    Kim, T.M.3
  • 111
    • 84906847643 scopus 로고    scopus 로고
    • Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
    • Adenis A, Blay JY, Bui-Nguyen B, et al. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. Ann Oncol. 2014;25(9):1762-1769.
    • (2014) Ann Oncol , vol.25 , Issue.9 , pp. 1762-1769
    • Adenis, A.1    Blay, J.Y.2    Bui-Nguyen, B.3
  • 112
    • 84908249084 scopus 로고    scopus 로고
    • A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent High-Grade glioma
    • Wuthrick EJ, Curran WJ, Camphausen K, et al. A Pilot Study of Hypofractionated Stereotactic Radiation Therapy and Sunitinib in Previously Irradiated Patients With Recurrent High-Grade Glioma. Int J Radiat Oncol Biol Phys. 2014;90(2):369-375.
    • (2014) Int J Radiat Oncol Biol Phys , vol.90 , Issue.2 , pp. 369-375
    • Wuthrick, E.J.1    Curran, W.J.2    Camphausen, K.3
  • 113
    • 84922576713 scopus 로고    scopus 로고
    • Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
    • Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2014;17(1):116-121.
    • (2014) Neuro Oncol , vol.17 , Issue.1 , pp. 116-121
    • Kaley, T.J.1    Wen, P.2    Schiff, D.3
  • 114
    • 84925545307 scopus 로고    scopus 로고
    • Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
    • Motzer RJ, Hutson TE, Hudes GR, et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014;74(4):739-750.
    • (2014) Cancer Chemother Pharmacol , vol.74 , Issue.4 , pp. 739-750
    • Motzer, R.J.1    Hutson, T.E.2    Hudes, G.R.3
  • 115
    • 84977136984 scopus 로고    scopus 로고
    • A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
    • Matsushita H, Enomoto Y, Kume H, et al. A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. J Immunother Cancer. 2014;2(1):1-11.
    • (2014) J Immunother Cancer , vol.2 , Issue.1 , pp. 1-11
    • Matsushita, H.1    Enomoto, Y.2    Kume, H.3
  • 116
    • 84921841165 scopus 로고    scopus 로고
    • Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial
    • Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177-186.
    • (2015) Lancet Oncol , vol.16 , Issue.2 , pp. 177-186
    • Thomas, A.1    Rajan, A.2    Berman, A.3
  • 117
    • 63049093371 scopus 로고    scopus 로고
    • Phase i trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma
    • Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(9):1432-1439.
    • (2009) J Clin Oncol , vol.27 , Issue.9 , pp. 1432-1439
    • Feldman, D.R.1    Baum, M.S.2    Ginsberg, M.S.3
  • 118
    • 65249102843 scopus 로고    scopus 로고
    • Phase i study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma
    • Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):24-27.
    • (2009) Clin Genitourin Cancer , vol.7 , Issue.1 , pp. 24-27
    • Patel, P.H.1    Senico, P.L.2    Curiel, R.E.3    Motzer, R.J.4
  • 119
    • 78650004173 scopus 로고    scopus 로고
    • Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Hudes GR, Ginsberg MS, et al. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol. 2010;33(6):614-618.
    • (2010) Am J Clin Oncol , vol.33 , Issue.6 , pp. 614-618
    • Motzer, R.J.1    Hudes, G.R.2    Ginsberg, M.S.3
  • 120
    • 78650536892 scopus 로고    scopus 로고
    • A phase i study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)
    • Grünwald V, Desar IME, Haanen J, et al. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta Oncol. 2011;50(1):121-126.
    • (2011) Acta Oncol , vol.50 , Issue.1 , pp. 121-126
    • Grünwald, V.1    Desar, I.M.E.2    Haanen, J.3
  • 121
    • 79551717184 scopus 로고    scopus 로고
    • Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
    • Rini BI, Stein M, Shannon P, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117(4):758-767.
    • (2011) Cancer , vol.117 , Issue.4 , pp. 758-767
    • Rini, B.I.1    Stein, M.2    Shannon, P.3
  • 122
    • 84860241870 scopus 로고    scopus 로고
    • A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
    • Bruce JY, Eickhoff J, Pili R, et al. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012;30(2):794-802.
    • (2012) Invest New Drugs , vol.30 , Issue.2 , pp. 794-802
    • Bruce, J.Y.1    Eickhoff, J.2    Pili, R.3
  • 123
    • 84858699792 scopus 로고    scopus 로고
    • Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
    • Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118(7):1868-1876.
    • (2012) Cancer , vol.118 , Issue.7 , pp. 1868-1876
    • Molina, A.M.1    Feldman, D.R.2    Voss, M.H.3
  • 124
    • 84866742044 scopus 로고    scopus 로고
    • Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma
    • Schmidinger M, Szczylik C, Sternberg CN, et al. Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol. 2012;35(5):493-497.
    • (2012) Am J Clin Oncol , vol.35 , Issue.5 , pp. 493-497
    • Schmidinger, M.1    Szczylik, C.2    Sternberg, C.N.3
  • 125
    • 84900319173 scopus 로고    scopus 로고
    • A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
    • Hong DS, Gordon MS, Samlowski WE, et al. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014;12(3):167-177.
    • (2014) Clin Genitourin Cancer , vol.12 , Issue.3 , pp. 167-177
    • Hong, D.S.1    Gordon, M.S.2    Samlowski, W.E.3
  • 126
    • 84896042886 scopus 로고    scopus 로고
    • A phase i pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
    • Bruce JY, Kolesar JM, Hammers H, et al. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol. 2014;73(3):485-493.
    • (2014) Cancer Chemother Pharmacol , vol.73 , Issue.3 , pp. 485-493
    • Bruce, J.Y.1    Kolesar, J.M.2    Hammers, H.3
  • 127
    • 84906854146 scopus 로고    scopus 로고
    • A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma
    • Rini B, Redman B, Garcia JA, et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol. 2014;25(9):1794-1799.
    • (2014) Ann Oncol , vol.25 , Issue.9 , pp. 1794-1799
    • Rini, B.1    Redman, B.2    Garcia, J.A.3
  • 128
    • 84906976089 scopus 로고    scopus 로고
    • Phase i Study of Sunitinib in Combination with Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma
    • Bellmunt J, Suarez C, Gallardo E, et al. Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma. Oncologist. 2014;19(9):917-918.
    • (2014) Oncologist , vol.19 , Issue.9 , pp. 917-918
    • Bellmunt, J.1    Suarez, C.2    Gallardo, E.3
  • 129
    • 84878222780 scopus 로고    scopus 로고
    • Accumulating Evidence and Research Organization (AERO) model: A new tool for representing, analyzing, and planning a translational research program
    • Hey SP, Heilig CM, Weijer C. Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials. 2013;14(1):159.
    • (2013) Trials , vol.14 , Issue.1 , pp. 159
    • Hey, S.P.1    Heilig, C.M.2    Weijer, C.3
  • 130
    • 7244243743 scopus 로고    scopus 로고
    • Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials
    • Roberts TG, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292(17):2130-2140.
    • (2004) JAMA , vol.292 , Issue.17 , pp. 2130-2140
    • Roberts, T.G.1    Goulart, B.H.2    Squitieri, L.3
  • 131
    • 84923861103 scopus 로고    scopus 로고
    • The structure of clinical translation: Efficiency information and ethics
    • Kimmelman J, London AJ. The Structure of Clinical Translation: Efficiency, Information, and Ethics. Hastings Cent Rep. 2015;45(2):27-39.
    • (2015) Hastings Cent Rep , vol.45 , Issue.2 , pp. 27-39
    • Kimmelman, J.1    London, A.J.2
  • 132
    • 67749145692 scopus 로고    scopus 로고
    • Publication outcomes of phase II oncology clinical trials
    • Hoeg RT, Lee JA, Mathiason MA, et al. Publication outcomes of phase II oncology clinical trials. Am J Clin Oncol. 2009;32(3):253-257.
    • (2009) Am J Clin Oncol , vol.32 , Issue.3 , pp. 253-257
    • Hoeg, R.T.1    Lee, J.A.2    Mathiason, M.A.3
  • 133
    • 77957048552 scopus 로고    scopus 로고
    • The need to consider the wider agenda in systematic reviews and meta-analyses: Breadth, timing, and depth of the evidence
    • Ioannidis JPA, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ. 2010;341.
    • (2010) BMJ , vol.341
    • Ioannidis, J.P.A.1    Karassa, F.B.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.